Adaptogenics Health Corp. (CSE: ADPT) has announced a non-brokered private placement offering of up to 2,500,000 units priced at $0.25 per unit, targeting gross proceeds of up to $625,000. Each unit comprises one common share and one-half of one common share purchase warrant, with full warrants exercisable at $0.75 for 24 months from issuance. The company intends to direct proceeds toward its ecommerce operations, nutritional products, peptide sourcing, and research and development activities. Investors focused on early-stage health and wellness companies may be watching the offering's progress closely.

Key Points

  • Adaptogenics Health Corp. (CSE: ADPT) is a Vancouver-based health sciences company focused on peptide and metabolic health opportunities.
  • The company announced a non-brokered private placement of up to 2,500,000 units at $0.25 per unit for gross proceeds of up to $625,000.
  • Warrants are exercisable at $0.75 per share for 24 months from issuance; securities are subject to a four-month-and-one-day hold period.
  • Investors should watch for Canadian Securities Exchange acceptance and closing of the offering in one or more tranches.

Unit Structure and Warrant Terms of the ADPT Private Placement

Each unit issued under the offering consists of one common share and one-half of one common share purchase warrant. Every whole warrant entitles the holder to acquire one additional common share at C$0.75 for a period of 24 months from the date of issuance. All securities issued are subject to a statutory hold period of four months and one day from issuance, in accordance with applicable Canadian securities laws. The offering is expected to close in one or more tranches and remains subject to regulatory approvals, including acceptance by the Canadian Securities Exchange.

How Adaptogenics Plans to Deploy the Offering Proceeds

The company states it intends to apply net proceeds toward advancing its ecommerce platform, nutritional products business, peptide sourcing activities, and research and development initiatives. Funds will also support personnel, investor relations, and general working capital requirements. Adaptogenics is evaluating proprietary peptide and small molecule opportunities focused on metabolic health, muscle preservation, mitochondrial biology, and inflammation, and is also exploring GLP-1 companion products intended to support nutritional health and muscle function in the context of medically induced weight loss.

Finder's Fees and U.S. Securities Restrictions

Adaptogenics may pay eligible finders a fee equal to 7% of units sold to subscribers they introduce, subject to applicable securities laws and Canadian Securities Exchange policies. The company notes that securities issued under this offering have not been registered under the United States Securities Act of 1933 and may not be offered or sold in the United States or to U.S. persons absent registration or an applicable exemption. The immediate share price impact was not clear from available public information.